That's standard accrual accounting, not the company.
Sales and other revenue broken down easily enough, and importantly the big one API Sales Revenue:
"Under the terms of the commercialisation agreement with Padagis, Acrux is currently responsible for the procurement of the Active Pharmaceutical Ingredients (‘API’) which are used in the commercial manufacture of Prilocaine 2.5% and Lidocaine 2.5%, Cream. These API purchases are recorded as Cost of Goods Sold and are in turn invoiced to Padagis and are included as Sales Revenue. The increased value of purchases and sales of Prilocaine and Lidocaine API reflect the increase in manufacturing activity relative to the prior comparative period, when the API had been purchased for the manufacture of launch stocks."
- Forums
- ASX - By Stock
- ACR
- Ann: Appendix 4D and Half Year Accounts
ACR
acrux limited
Add to My Watchlist
0.00%
!
2.0¢

Ann: Appendix 4D and Half Year Accounts, page-7
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.155M |
Open | High | Low | Value | Volume |
2.1¢ | 2.2¢ | 2.0¢ | $7.942K | 390.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 565571 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.2¢ | 27574 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 565571 | 0.020 |
4 | 451342 | 0.019 |
1 | 160000 | 0.018 |
2 | 469000 | 0.017 |
1 | 66732 | 0.015 |
Price($) | Vol. | No. |
---|---|---|
0.022 | 27574 | 2 |
0.023 | 125126 | 5 |
0.024 | 306848 | 8 |
0.025 | 268239 | 2 |
0.026 | 75000 | 3 |
Last trade - 14.59pm 17/06/2025 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
RC1
REDCASTLE RESOURCES LIMITED
Ronald Miller, Non-Executive Director
Ronald Miller
Non-Executive Director
SPONSORED BY The Market Online